BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
2 Hyun HK, Zhang H, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02225-w] [Reference Citation Analysis]
3 Verstockt B, Parkes M, Lee J. How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? Gastroenterology 2022:S0016-5085(21)04081-6. [PMID: 34995535 DOI: 10.1053/j.gastro.2021.12.245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
4 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
5 Cao Y, Dai Y, Zhang L, Wang D, Hu W, Yu Q, Wang X, Yu P, Liu W, Ping Y, Sun T, Sang Y, Liu Z, Chen Y, Tao Z. Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin. J Inflamm Res 2021;14:6409-19. [PMID: 34880643 DOI: 10.2147/JIR.S342846] [Reference Citation Analysis]
6 Geyer CE, Newling M, Sritharan L, Griffith GR, Chen HJ, Baeten DLP, den Dunnen J. C-Reactive Protein Controls IL-23 Production by Human Monocytes. Int J Mol Sci 2021;22:11638. [PMID: 34769069 DOI: 10.3390/ijms222111638] [Reference Citation Analysis]
7 Kang EA, Park JW, Park Y, Park SJ, Kim TI, Kim WH, Cho MS, Cheon JH. C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet's disease. BMC Gastroenterol 2021;21:362. [PMID: 34620099 DOI: 10.1186/s12876-021-01922-2] [Reference Citation Analysis]
8 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Reference Citation Analysis]
9 Wright E. Non-invasive biomarkers as treatment targets: What do we all need to know? J Gastroenterol Hepatol 2021;36 Suppl 1:12-3. [PMID: 33817840 DOI: 10.1111/jgh.15449] [Reference Citation Analysis]
10 Zhao H, Liu H, Qi W, Liu W, Ye L, Cao Q, Ge X, Zhou W, Wang X. Postoperative Ratio of C-Reactive Protein to Albumin as a Predictive Marker in Patients with Crohn's Disease Undergoing Bowel Resection. Gastroenterol Res Pract 2021;2021:6629608. [PMID: 33727917 DOI: 10.1155/2021/6629608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study. Medicine (Baltimore) 2021;100:e24717. [PMID: 33578614 DOI: 10.1097/MD.0000000000024717] [Reference Citation Analysis]
12 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn's disease. Lancet Gastroenterol Hepatol 2020;5:80-92. [PMID: 31818474 DOI: 10.1016/S2468-1253(19)30340-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
14 Liu X, Sun J, Wen X, Duan J, Xue D, Pan Y, Sun J, Zhang W, Cheng X, Wang C. Proteome profiling of gestational diabetes mellitus at 16-18 weeks revealed by LC-MS/MS. J Clin Lab Anal 2020;34:e23424. [PMID: 32537767 DOI: 10.1002/jcla.23424] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Coates MD, Soriano C, Dalessio S, Stuart A, Walter V, Koltun W, Bernasko N, Tinsley A, Clarke K, Williams ED. Gastrointestinal hypoalgesia in inflammatory bowel disease. Ann Gastroenterol 2020;33:45-52. [PMID: 31892797 DOI: 10.20524/aog.2019.0442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21:111. [PMID: 31046809 DOI: 10.1186/s13075-019-1882-2] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 32.7] [Reference Citation Analysis]
17 Ma C, Battat R, Khanna R, Parker CE, Feagan BG, Jairath V. What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity? Best Pract Res Clin Gastroenterol 2019;38-39:101602. [PMID: 31327404 DOI: 10.1016/j.bpg.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Monteiro S, Dias de Castro F, Leite S, Moreira MJ, Cotter J. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question. Scand J Gastroenterol 2019;54:49-54. [PMID: 30663515 DOI: 10.1080/00365521.2018.1549683] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Ma C, Battat R, Parker CE, Khanna R, Jairath V, Feagan BG. Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn’s disease? Expert Review of Gastroenterology & Hepatology 2019;13:319-30. [DOI: 10.1080/17474124.2019.1563481] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
20 Vecchié A, Bonaventura A, Carbone F, Maggi D, Ferraiolo A, Carloni B, Andraghetti G, Affinito Bonabello L, Liberale L, Dallegri F, Montecucco F, Cordera R. C-Reactive Protein Levels at the Midpregnancy Can Predict Gestational Complications. Biomed Res Int 2018;2018:1070151. [PMID: 30533423 DOI: 10.1155/2018/1070151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology 2018;155:76-87. [PMID: 29601825 DOI: 10.1053/j.gastro.2018.03.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
22 Park JH, Nam HN, Lee JH, Hong J, Yi DY, Ryoo E, Jeon IS, Tchah H. Characteristics of Upper Gastrointestinal Tract Involvement in Korean Pediatric Crohn's Disease: A Multicenter Study. Pediatr Gastroenterol Hepatol Nutr 2017;20:227-35. [PMID: 29302504 DOI: 10.5223/pghn.2017.20.4.227] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]